Literature DB >> 3099227

Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis.

R H Brown, D Johnson, M Ogonowski, H L Weiner.   

Abstract

Sera from 12 patients with amyotrophic lateral sclerosis (ALS) and 18 controls were screened for antineural antibodies using immunoblotting. No consistent differences were detected between ALS patients and controls, although antibodies to 52,000- and 70,000-dalton proteins in mouse spinal cord were somewhat more common in ALS sera. Antibodies to a protein of approximately 150,000 to 200,000 daltons were also evident. The 70,000- and 52,000-dalton proteins were detected in brain, cerebellum, and liver as well as spinal cord. Immunohistochemistry suggested antibody activity was directed at least in part to neurofilaments. While the antibodies to the 52,000- and 70,000-dalton proteins were more common in ALS than control sera (p less than 0.02 and less than 0.05, respectively), it is not clear from this initial study that this difference is of clinical or etiologic significance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3099227     DOI: 10.1212/wnl.37.1.152

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease.

Authors:  Oliver Stich; Barbara Kleer; Sebastian Rauer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-21       Impact factor: 10.154

2.  Intramuscular nerves in motor neurone disease. A quantitative ultrastructural study.

Authors:  C P Case; M Jelaca
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

3.  A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  A Stevens; M Weller; H Wiethölter
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

4.  Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease.

Authors:  L Soussan; K Tchernakov; O Bachar-Lavi; T Yuvan; E Wertman; D M Michaelson
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.